1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1) : a multicentre, randomised, phase 2 trial
(
- Contribution to journal › Article
- 2020
-
Mark
Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version
(
- Contribution to journal › Article
- 2017
-
Mark
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
(
- Contribution to journal › Article
- 2012
-
Mark
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study.
(
- Contribution to journal › Article
- 1992
-
Mark
Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases-A prospective randomised placebo-controlled multicentre study
(
- Contribution to journal › Article